Associated Papers
Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.
Muñoz-Mármol AM et al.
Cancers, 2025
39941744 (PubMed )
Supplement: cancers-17-00375-s001.zip › cancers-3382881-Supplementary_Table_S3.xlsx › Hoja1
Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.
Brunner C et al.
Journal of Clinical Immunology, 2002
Select a paper to view details